Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Blazquez, Rebeca ^a   Sanchez Margallo, Francisco Miguel ^a   de la Rosa, Olga ^b   Dalemans, Wilfried ^c   Álvarez, Verónica ^a   Tarazona, Raquel ^d   Casado, Javier G ^a  

^a JESÚS USÓN MINIMALLY INVASIVE SURGERY CENTRE   (Spain)

^b TiGenix   (Spain)

^c Technical Operations   (Belgium)

^d UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Exosomes; Immunomodulation; Lymphocyte activation; Lymphocytes; Mesenchymal stem cells

Indexed keywords

CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON;

ADIPOSE DERIVED STEM CELL; ADULT; ARTICLE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER CELL PROLIFERATION ASSAY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; EXOSOME; HUMAN; HUMAN ADIPOSE MESENCHYMAL STEM CELLS DERIVED EXOSOME; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE DIFFERENTIATION; MESENCHYMAL STEM CELL; NORMAL HUMAN; PHENOTYPE; PROTEIN DETERMINATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84919421853     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00556     Document Type: Article

References (47)

1. Mathivanan S, Simpson RJ. ExoCarta: a compendium of exosomal proteins and RNA. Proteomics (2009) 9:4997-5000. doi: 10.1002/pmic.200900351
2. Raimondo F, Morosi L, Chinello C, Magni F, Pitto M. Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Proteomics (2011) 11:709-20. doi:10.1002/pmic.201000422
3. Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles (2013) 2:20360. doi:10.3402/jev.v2i0.20360
4. Kittel A, Falus A, Buzás E. Microencapsulation technology by nature: cell derived extracellular vesicles with therapeutic potential. Eur J Microbiol Immunol (2013) 3:91-6. doi:10.1556/EuJMI.3.2013.2.1
5. Beauvillain C, Juste MO, Dion S, Pierre J, Dimier-Poisson I. Exosomes are an effective vaccine against congenital toxoplasmosis in mice. Vaccine (2009) 27:1750-7. doi:10.1016/j.vaccine.2009.01.022
6. Kuate S, Cinatl J, Doerr HW, Uberla K. Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies. Virology (2007) 362:26-37. doi:10.1016/j.virol.2006.12.011
7. Prado N, Marazuela EG, Segura E, Fernández-García H, Villalba M, Théry C, et al. Exosomes from bronchoalveolar fluid of tolerized mice prevent allergic reaction. J Immunol (2008) 181:1519-25. doi:10.4049/jimmunol.181.2.1519
8. Cai Z, Zhang W, Yang F, Yu L, Yu Z, Pan J, et al. Immunosuppressive exosomes from TGF-β1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res (2012) 22:607-10. doi:10.1038/cr.2011.196
9. Yin W, Ouyang S, Li Y, Xiao B, Yang H. Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity. Inflammation (2013) 36:232-40. doi:10.1007/s10753-012-9539-1
10. Pêche H, Heslan M, Usal C, Amigorena S, Cuturi MC. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation (2003) 76:1503-10. doi:10.1097/01.TP.0000092494.75313.38
11. Pêche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi MC. Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant (2006) 6:1541-50. doi:10.1111/j.1600-6143.2006.01344.x
12. Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res (2010) 70:1281-5. doi:10.1158/0008-5472.CAN-09-3276
13. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther (2008) 16:782-90. doi:10.1038/mt.2008.1
14. Lai RC, Chen TS, Lim SK. Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease. Regen Med (2011) 6:481-92. doi:10.2217/rme.11.35
15. Sahoo S, Klychko E, Thorne T, Misener S, Schultz KM, Millay M, et al. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res (2011) 109:724-8. doi:10.1161/CIRCRESAHA.111.253286
16. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci (2014) 15:4142-57. doi:10.3390/ijms15034142
17. Chimenti I, Smith RR, Li T-S, Gerstenblith G, Messina E, Giacomello A, et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res (2010) 106:971-80. doi:10.1161/CIRCRESAHA.109.210682
18. Maguire G. Stem cell therapy without the cells. Commun Integr Biol (2013) 6:e26631. doi:10.4161/cib.26631
19. Casado JG, Tarazona R, Sanchez-Margallo FM. NK and MSCs crosstalk: the sense of immunomodulation and their sensitivity. Stem Cell Rev (2013) 9:184-9. doi:10.1007/s12015-013-9430-y
20. de la Rosa O, Sánchez-Correa B, Morgado S, Ramírez C, del Río B, Menta R, et al. Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev (2012) 21:1333-43. doi:10.1089/scd.2011.0139
21. Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J Leukoc Biol (2007) 82:887-93. doi:10.1189/jlb.0307140
22. Prigione I, Benvenuto F, Bocca P, Battistini L, Uccelli A, Pistoia V. Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells (2009) 27:693-702. doi:10.1634/stemcells.2008-0687
23. Chen L, Zhang W, Yue H, Han Q, Chen B, Shi M, et al. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev (2007) 16:719-31. doi:10.1089/scd.2007.0065
24. Ramasamy R, Fazekasova H, Lam EW-F, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation (2007) 83:71-6. doi:10.1097/01.tp.0000244572.24780.54
25. Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, et al. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells (2008) 26:1275-87. doi:10.1634/stemcells.2007-0878
26. Geginat J, Lanzavecchia A, Sallusto F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood (2003) 101:4260-6. doi:10.1182/blood-2002-11-3577
27. Okada R, Kondo T, Matsuki F, Takata H, Takiguchi M. Phenotypic classification of human CD4+ T cell subsets and their differentiation. Int Immunol (2008) 20:1189-99. doi:10.1093/intimm/dxn075
28. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion (2014) 54:1418-37. doi:10.1111/trf.12421
29. Plant AL, Parker GC. Translating stem cell research from the bench to the clinic: a need for better quality data. Stem Cells Dev (2013) 22:2457-8. doi:10.1089/scd.2013.0188
30. de la Rosa O, Lombardo E, Beraza A, Mancheño-Corvo P, Ramirez C, Menta R, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A (2009) 15:2795-806. doi:10.1089/ten. TEA.2008.0630
31. Franquesa M, Hoogduijn MJ, Bestard O, Grinyó JM. Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol (2012) 3:212. doi:10.3389/fimmu.2012.00212
32. Liu W, Liu J, Wu J, Zhang L, Liu F, Yin L, et al. Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One (2013) 8:e55487. doi:10.1371/journal.pone.0055487
33. Engela AU, Baan CC, Peeters AMA, Weimar W, Hoogduijn MJ. Interaction between adipose tissue-derived mesenchymal stem cells and regulatory T-cells. Cell Transplant (2013) 22:41-54. doi:10.3727/096368912X636984
34. Engela AU, Baan CC, Dor FJ, Weimar W, Hoogduijn MJ. On the interactions between mesenchymal stem cells and regulatory T cells for immunomodulation in transplantation. Front Immunol (2012) 3:126. doi:10.3389/fimmu.2012.00126
35. Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. Circ Res (2014) 114:333-44. doi:10.1161/CIRCRESAHA.114.300639
36. Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther (2013) 4:34. doi:10.1186/scrt194
37. Kordelas L, Rebmann V, Ludwig A-K, Radtke S, Ruesing J, Doeppner TR, et al. MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia (2014) 28:970-3. doi:10.1038/leu.2014.41
38. Xin H, Li Y, Buller B, Katakowski M, Zhang Y, Wang X, et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells (2012) 30:1556-64. doi:10.1002/stem.1129
39. Ludwig A, Kordelas L, Rebmann V, Radtke S, Felderhoff-Müser U, Horn P, et al. Exosomes - from bench to bedside. Klin Pädiatr (2012) 224:A6. doi:10.1055/s-0032-1330775
40. Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid A-A, Mardani K. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol Lett (2012) 147:47-54. doi:10.1016/j.imlet.2012.06.001
41. Zhang B, Yin Y, Lai RC, Tan SS, Choo ABH, Lim SK. Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells Dev (2014) 23:1233-44. doi:10.1089/scd.2013.0479
42. Trickett A, Kwan YL. T cell stimulation and expansion using anti-CD3/CD28 beads. J Immunol Methods (2003) 275:251-5. doi:10.1016/S0022-1759(03)00010-3
43. Dorronsoro A, Ferrin I, Salcedo JM, Jakobsson E, Fernández-Rueda J, Lang V, et al. Human mesenchymal stromal cells modulate T-cell responses through TNF-α-mediated activation of NF-κB. Eur J Immunol (2014) 44:480-8. doi:10.1002/eji.201343668
44. Hoogduijn MJ, Crop MJ, Peeters AM, Van Osch GJ, Balk AH, Ijzermans JN, et al. Human heart, spleen, and perirenal fat-derived mesenchymal stem cells have immunomodulatory capacities. Stem Cells Dev (2007) 16:597-604. doi:10.1089/scd.2006.0110
45. Maguire G, Friedman P, McCarthy D, Friedman R, Maniotis A. Stem cell released molecules and exosomes in tissue engineering. Procedia Eng (2013) 59:270-8. doi:10.1016/j.proeng.2013.05.121
46. Crop MJ, Korevaar SS, de Kuiper R, IJzermans JNM, van Besouw NM, Baan CC, et al. Human mesenchymal stem cells are susceptible to lysis by CD8(+) T cells and NK cells. Cell Transplant (2011) 20:1547-59. doi:10.3727/096368910X564076
47. Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, de Kleijn DP, et al. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics (2012) 2012:971907. doi:10.1155/2012/971907